OSE Immunotherapeutics: its chief executive officer expected on October 20 in New York at Chardan
The Nantes-based biotech announced, in a press release published on October 15, 2026, the participation of its management at the 10th annual conference dedicated to healthcare organized by Chardan. This is an agenda communication intended for investors, without any announcement of new strategic decisions.
Chief Executive Officer Interview and Meetings with Investors
The conference will be held on October 20, 2026 at The Lotte New York Palace hotel in New York. Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics, will participate in a "fireside chat" type interview, a question-and-answer discussion, scheduled for 1:15 p.m. New York time (7:15 p.m. Paris time).
Management will also hold meetings with investors on the sidelines of the event.
A clinical-stage biotech in immuno-oncology and immuno-inflammation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
OSE Immunotherapeutics presents itself as a clinical-stage biotechnology company that develops "first-in-class" therapies in immuno-oncology and immuno-inflammation. The group indicates that it is partnering with academic institutions and biopharmaceutical companies to develop its assets. Based between Nantes and Paris, the company is listed on Euronext.
On September 28, 2026, when publishing its cash position as of June 30, 2026, it had indicated that it was continuing discussions with institutional investors in the United States and Europe with a view to extending its financing horizon.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T1 2026
Risks mentioned
Taux de trésorerie et équivalents de trésorerie de 17,0 millions d'euros au 31 mars 2026 en baisse.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
